"
Template:SupbiotechparisFr
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
|||
| Line 64: | Line 64: | ||
<span style="color: black;">'''Concept DVS'''</span> | <span style="color: black;">'''Concept DVS'''</span> | ||
[[Team:SupBiotech-Paris/Introduction1Fr|Introduction]] | [[Team:SupBiotech-Paris/Introduction1Fr|Introduction]] | ||
| - | [[Team:SupBiotech-Paris/Concept1Fr| | + | [[Team:SupBiotech-Paris/Concept1Fr|Vecteur Tissulaire]] |
| - | [[Team:SupBiotech-Paris/Concept2Fr| | + | [[Team:SupBiotech-Paris/Concept2Fr|Vecteur Cellulaire]] |
[[Team:SupBiotech-Paris/Concept3Fr|Plasmide d'apoptose]] | [[Team:SupBiotech-Paris/Concept3Fr|Plasmide d'apoptose]] | ||
[[Team:SupBiotech-Paris/Conclusion1Fr|Conclusion]] | [[Team:SupBiotech-Paris/Conclusion1Fr|Conclusion]] | ||
Revision as of 11:58, 21 September 2009
Projet
Introduction Thérapies actuelles Thérapies géniques Concept DVS Introduction Vecteur Tissulaire Vecteur Cellulaire Plasmide d'apoptose Conclusion Mise en application Ciblage Tissulaire Ciblage Cellulaire Modélisation cancer Conclusion
Ressources
Biobricks Matériel & Méthode Bibliographie
Ethique & sûreté
Biologie Synthetique Notre projet Sûreté
